
Opinion|Videos|November 20, 2025
Subgroup Analysis From the Phase 3 EMERALD Trial by Prior Duration of Endocrine Therapy Plus CDK4/6 Inhibitor
Elacestrant significantly improved progression-free survival and maintained a manageable safety profile, especially benefiting patients with ESR1-mutated tumors.
Advertisement
Episodes in this series

An additional subgroup analysis examined outcomes based on prior endocrine therapy (ET) duration and CDK4/6 inhibitor exposure. Patients with a longer prior duration of ET plus CDK4/6 inhibitor showed a clinically meaningful improvement in PFS when treated with elacestrant compared to standard of care. This suggests that tumors retaining partial endocrine sensitivity particularly with ESR1 mutations—derive the greatest benefit from selective estrogen receptor degrader-based therapy.
Advertisement
Related to this article

A Centene OB-GYN and an AAFP family physician explain how health plans, primary care and policy can help close rural maternity care gaps.

Nelkarmi gives ALK-positive lung cancer patients a new option after first-line therapy stops working
The FDA granted accelerated approval to GSK's Nelkarmi for previously treated ALK-positive NSCLC, the company's second lung cancer approval this year.

A pooled review of 40 studies tied type 2 diabetes to a 53% higher Alzheimer’s risk, with incidence more than doubling when clinicians made the diagnosis.

Lockton's Sarah Klein says employers are already asking hard questions about PBM transparency, even though many of the new rules have not taken effect.

WIC participation is estimated at only 44% of eligible Medicaid enrollees in 2023, and just 15% of pregnant Medicaid enrollees. Health plans can help close that gap, but only if their referrals are tracked through enrollment.

Heidi Overton ran into opposition from Republican senators concerned about her role in setting White House vaccine policy.

In more than 256,000 adults with prediabetes and obesity, GLP-1s were linked to better blood sugar and heart outcomes than metformin, according to a study presented at the American Heart Association (AHA) Scientific Sessions 2026.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Closing rural maternity care gaps starts close to home, Centene and AAFP leaders say
2
Type 2 diabetes associated with 53% higher Alzheimer’s risk, with claims data likely undercounting cases, review shows
3
Takeda launches Orzeyful, first orexin agonist for narcolepsy type 1
4
Quick Q&A: Sarah Klein on scrutinizing PBM contracts
5


